Advertisement
Table 1 Patient demographics and disease characteristics at baseline
| KRASPRO analysis set | PRO analysis set | ||
|---|---|---|---|
| WT KRAS(n = 76) | MT KRAS(n = 54) | Overall (n = 137) | |
| Sex, n (%) | |||
| Male | 61 (80) | 29 (54) | 95 (69) |
| Female | 15 (20) | 25 (46) | 42 (31) |
| Race/ethnicity, n (%) | |||
| White/Caucasian | 73 (96) | 53 (98) | 133 (97) |
| Black/African American | 2 (3) | 0 (0) | 2 (1) |
| Hispanic/Latino | 0 (0) | 1 (2) | 1 (1) |
| Japanese | 1 (1) | 0 (0) | 1 (1) |
| Median age, years (range) | 63.5 (21–84) | 65.0 (37–80) | 64.0 (21–84) |
| Age group, n (%) | |||
| <65 years | 40 (53) | 26 (48) | 71 (52) |
| ≥65 years | 36 (47) | 28 (52) | 66 (48) |
| <75 years | 71 (93) | 44 (81) | 121 (88) |
| ≥75 years | 5 (7) | 10 (19) | 16 (12) |
| Primary tumour type, n (%) | |||
| Colon cancer | 43 (57) | 36 (67) | 82 (60) |
| Rectal cancer | 33 (43) | 18 (33) | 55 (40) |
| Number of metastatic sites, n (%) | |||
| 1 | 33 (43) | 23 (43) | 63 (46) |
| 2 | 22 (29) | 19 (35) | 41 (30) |
| ≥3 | 21 (28) | 12 (22) | 33 (24) |
| Location of metastatic sites, n (%) | |||
| Liver only | 28 (37) | 15 (28) | 46 (34) |
| Liver plus other sites | 35 (46) | 25 (46) | 60 (44) |
| Other sites only | 13 (17) | 14 (26) | 31 (23) |
| ECOG performance status, n (%) | |||
| 0 | 43 (57) | 30 (56) | 80 (58) |
| 1 | 30 (39) | 20 (37) | 50 (36) |
| 2 | 3 (4) | 4 (7) | 7 (5) |
| Mean (SD) PRO scores | |||
| EQ-5D health state index | 0.81 (0.22) | 0.80 (0.22) | 0.81 (0.22) |
| EQ-5D overall health rating | 71.7 (20.1) | 71.9 (19.6) | 72.5 (19.8) |
| QLQ-C30 global health status | 64.4 (22.5) | 65.1 (22.8) | 65.8 (22.5) |
